AMRX250117C7500
- 0.70
- 0.000.00%
Amneal Pharmaceuticals Newsroom
Amneal Announces FDA Approval For Dementia And Oncology Therapies, Tentative Approval For IBS-D Drug; 180-Day Exclusivity For Memantine/Donepezil
Express News | Amneal Pharma - Approval of Three Important Therapies for Dementia, Oncology and Gastrointestinal Disease
Express News | Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
RBC on FDA's Third Tentative Approval For Rifaximin 550mg to Amneal Pharmaceuticals
FDA Grants Tentative Approval for Amneal Generic of Bausch Health's Xiafan
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Amneal Pharmaceuticals Maintains Transparency With SEC Filing
Express News | Amneal Pharmaceuticals Inc - Expects to Meet or Exceed 2024 Financial Guidance
Amneal (AMRX) Upgraded to Strong Buy: Here's Why
Here's Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10
Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $11
Amneal to Participate at Upcoming Investor Conferences
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Sector Update: Health Care Stocks Advance Premarket Friday
Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved
Express News | Amneal Pharmaceuticals Inc - FDA Review of Dhe Autoinjector Nda Expected by Q2 2025
Express News | Amneal Resubmits Dhe Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, Its First Generic Injectable GLP-1 Agonist
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, Its First Generic Injectable GLP-1 Agonist
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS